Since 2010, the Global Law Experts annual awards have been celebrating excellence, innovation and performance across the legal communities from around the world.
posted 3 hours ago
Last reviewed: July 3, 2026
The question of AI prior art in Canada has moved from academic curiosity to operational emergency for every biotech and pharmaceutical patent team in the country. CIPO’s March 2026 practice notice on patentable subject‑matter sharpened the rules that examiners apply when assessing computer‑implemented and AI‑assisted inventions, and, by extension, intensified scrutiny of AI‑generated disclosures that may be cited against pending applications. At the same time, the global regulatory landscape is converging: the USPTO published its own request for comments on the proliferation of AI‑generated prior art in 2024, and WIPO continues to develop policy guidance on AI and intellectual property.
For in‑house counsel, patent prosecutors and R&D leaders at life‑sciences companies operating in Canada, the practical imperative is clear: understand exactly when an AI output becomes citable prior art, when a prompt becomes a public disclosure, and what to do in prosecution and litigation when either scenario materialises.
Short answer: Yes, in principle, any AI‑generated content that is publicly accessible and technically enabling can be cited as prior art against a Canadian patent application.
Under the Patent Act (R.S.C., 1985, c. P‑4), novelty is assessed against information that has been made available to the public before the claim date. Section 28.2 provides that the subject‑matter of a claim must not have been disclosed in such a way that it became available to the public in Canada or elsewhere. The statute does not distinguish between human‑authored and machine‑generated disclosures. If an AI output is posted on an indexed website, a public repository, a preprint server, a social‑media thread or any other medium accessible without restriction, it satisfies the availability requirement for prior art under Canadian law.
CIPO’s own guidance on filing prior art confirms that any person may submit prior art against a pending patent application. The format of that prior art, whether a journal article, a technical specification, or a text output generated by a large language model, is immaterial. What matters is the combination of public accessibility, a determinable date, and technical content that is relevant to the claims at issue.
Not every AI‑generated text qualifies as an enabling disclosure. Under the anticipation framework developed by the Federal Court, a prior art reference must disclose the invention in a manner that allows a person skilled in the art to practise it without undue experimentation. AI outputs can range from highly specific (a machine‑learning model suggesting a particular antibody CDR sequence with binding data) to demonstrably unreliable (a hallucinated synthesis route that no chemist could replicate). The critical question is whether the AI‑generated content, read by a skilled person, conveys enough information to arrive at the claimed invention.
Industry observers expect that examiners and courts will increasingly encounter a spectrum of AI prior art in Canada, from detailed computational chemistry predictions to vague generative text, and will need to assess enablement on a case‑by‑case basis. For biotech and pharma, the risk is highest where AI tools produce plausible molecular structures, target‑binding predictions, or formulation parameters that closely mirror a company’s proprietary research.
| AI output type | How it can qualify as prior art |
|---|---|
| Public forum post containing an AI‑generated peptide sequence with predicted activity data | Publicly accessible, date‑stamped, and potentially enabling if a skilled person can verify or replicate the prediction |
| GitHub repository with an AI model outputting drug–target interaction scores | Indexed and accessible; if the output identifies a specific compound‑target pair with enough detail, it may anticipate a method‑of‑treatment claim |
| AI‑generated image of a protein structure posted on a preprint server | Meets accessibility and date requirements; enablement turns on whether the structural data allows synthesis or functional use |
| Chatbot conversation screenshot shared on social media describing a novel formulation approach | Public disclosure with a retrievable date; enablement depends on the specificity and accuracy of the formulation details |
| AI‑drafted patent‑style specification uploaded to an open‑access database | Highly likely to be enabling if written in patent‑specification format with examples and data |
The consistent thread across these scenarios is that the Patent Act tests are technology‑neutral. The source of the disclosure, human or machine, does not change the legal analysis. What matters for ai prior art in Canada is whether the content was available, dated and sufficiently detailed to meet the anticipation or obviousness threshold.
Short answer: Possibly. Entering proprietary research data into a public or third‑party AI tool creates prompt engineering patent risk because the information may be stored, used for model training, or surfaced to other users, any of which could constitute a public disclosure that destroys novelty.
The concept of public disclosure under Canadian patent law is broad. A disclosure occurs when information is made available to even one member of the public without an obligation of confidence. When a researcher types a novel compound structure or an experimental protocol into a publicly available AI chatbot, the terms of service of that tool typically grant the provider a licence to use, store and sometimes display the input. Even where outputs are not immediately re‑published, the potential for the provider to use prompts in training data means that the information may eventually surface in responses to other users, a chain of events that, early indications suggest, could be treated as making the information available to the public.
Every pharma and biotech organisation should implement a before‑you‑prompt policy to manage the risk of inadvertent public disclosure via AI tools. The following operational controls represent industry‑emerging best practice:
Operational controls alone are insufficient if the vendor’s terms of service allow broad data reuse. In‑house counsel should negotiate, or, where standard consumer terms apply, escalate to enterprise agreements that include, the following protections:
Without these clauses, the likely practical effect is that any prompt containing patentable information entered into a third‑party AI tool will be treated, by a diligent examiner or an opposing litigator, as a potential public disclosure.
CIPO’s March 2026 practice notice updated examiner guidance on patentable subject‑matter for computer‑implemented inventions, including those involving AI or machine‑learning components. The notice reinforces that, for an invention to be patentable subject‑matter in Canada, there must be a physical embodiment or a practical application, a requirement that has particular significance for biotech and pharma applicants seeking to protect AI‑assisted discoveries.
The practice notice directs examiners to assess whether the essential elements of a claimed invention include a component that falls within the statutory categories of art, process, machine, manufacture, or composition of matter. Where an AI algorithm is merely a tool used in the inventive process, the invention itself, for example, a new compound, a diagnostic method, or a formulation, remains patentable provided the claims are properly directed to the physical or practical result. However, where the claims are directed solely to an abstract AI methodology without a tangible technical output, examiners are instructed to raise subject‑matter objections under section 2 of the Patent Act.
For biotech patent drafting in Canada, the CIPO 2026 practice notice means that applicants must anchor AI‑related claims to concrete biological or chemical outcomes. Claims to “a method of using a machine‑learning model to identify candidate molecules” will face scrutiny unless the claim also recites a tangible step, synthesis, in‑vitro testing, administration to a subject, or formulation into a dosage form. The practical implication is that prosecution teams should draft claims with explicit physical endpoints and avoid framing the AI component as the inventive contribution in isolation.
In a landscape increasingly saturated with AI‑generated prior art in Canada, claim‑drafting strategy is the first line of defence. The goal is to craft claims that are robust against both conventional and AI‑generated prior art challenges while complying with CIPO’s patentable subject‑matter standards.
Consider the following contrasting approaches for a biotech invention discovered with AI assistance:
Risky claim language:
“A method of identifying a compound that binds to Target X, comprising inputting structural data into a machine‑learning model and selecting a candidate compound from the model’s output.”
This claim is vulnerable on two fronts. First, an AI model could generate the same or a similar output, creating citable prior art. Second, the claim may be challenged as non‑statutory subject‑matter because it recites an abstract computational method without a physical endpoint.
Resilient claim language:
“A pharmaceutical composition comprising Compound Y that binds to Target X with a Kd of less than 10 nM, wherein Compound Y has the structure defined in Formula I, and a pharmaceutically acceptable carrier.”
This claim is anchored to a specific compound, measurable binding data and a tangible composition. An AI output predicting a generic class of binders would be unlikely to anticipate the specific compound, and the claim clearly recites statutory subject‑matter.
Additional drafting principles for biotech patent drafting in Canada include:
For pharma and biotech applicants, a pharma patent filing checklist should include contemporaneous documentation of every experimental step, from computational prediction through wet‑lab validation. Maintain laboratory notebooks (electronic or physical) with witnessed entries, retain raw assay data, and archive correspondence between computational and experimental teams. If AI tools were used at any stage, the prompt log and outputs should be preserved alongside the experimental records to establish the full inventive pathway.
When AI‑generated prior art is cited against a patent in Federal Court proceedings or in a proceeding under the Patented Medicines (Notice of Compliance) Regulations, the response must be swift, technically rigorous and forensically sound. The following playbook outlines the key steps.
The first 48 hours after receiving a citation of AI‑generated prior art are critical. Litigation counsel should immediately trigger an internal preservation protocol:
Authentication of AI‑generated prior art raises specific evidentiary challenges. The output must be shown to have existed in its cited form on or before the relevant date. Hearsay objections may arise if the AI output is offered for the truth of its technical content without an authenticating witness. Counsel should prepare affidavit evidence from the person who retrieved the output, from the AI vendor (if cooperative), and from the forensics expert who can confirm the chain of custody.
When defending against AI prior art citations, consider the following tactical approaches in Federal Court and PM(NOC) proceedings:
| Response step | Responsible team (in‑house / external) | Typical timeline |
|---|---|---|
| Preserve AI prompts & outputs (prompt log) | R&D + IT + outside counsel | 0–48 hours |
| Subpoena / request vendor logs and model metadata | Outside counsel | 3–14 days |
| Forensic analysis & expert report | External technical expert | 2–6 weeks |
| Wet‑lab replication testing of AI output | Internal R&D + external expert | 4–8 weeks |
| File evidence / motions in PM(NOC) or Federal Court | Litigation counsel | Aligned with procedural schedule |
Implementing policy is only effective when the right tools are distributed to every team that touches patentable information. The following resources should be developed, maintained and updated quarterly:
Templates alone do not change behaviour. Each resource should be accompanied by a mandatory training module, delivered at onboarding and refreshed quarterly, that includes scenario‑based exercises. For example, present researchers with a realistic prompt scenario and ask them to classify the risk, apply the policy, and log the prompt correctly. Track completion rates and tie compliance to performance reviews. The goal is to embed before‑you‑prompt thinking into the daily workflow of every team member who interacts with AI tools.
The intersection of AI prior art and Canadian patent law demands immediate, practical action from every biotech and pharmaceutical organisation. Pause all public prompting of proprietary R&D data today. Implement prompt‑logging and a before‑you‑prompt policy within the current quarter. Audit existing patent applications for any prior AI‑tool exposure. Brief litigation teams on the evidence‑preservation and authentication playbook outlined above. And consult qualified patent counsel experienced in both life‑sciences prosecution and Federal Court litigation to conduct a tailored AI prior art risk audit, because in the 2026 landscape, the cost of inaction is measured in lost patent rights.
This article was produced by Global Law Experts. For specialist advice on this topic, contact Marian Wolanski at BELMORE NEIDRAUER LLP, a member of the Global Law Experts network.
Find the right Legal Expert for your business
Sign up for the latest advisor briefings and news within Global Advisory Experts’ community, as well as a whole host of features, editorial and conference updates direct to your email inbox.
Naturally you can unsubscribe at any time.
Global Advisory Experts is dedicated to providing exceptional advisory services to clients around the world. With a vast network of highly skilled and experienced advisors, we are committed to delivering innovative and tailored solutions to meet the diverse needs of our clients in various jurisdictions.
